Cardlytics Inc (NASDAQ:CDLX) – Equities research analysts at William Blair issued their Q2 2019 earnings per share estimates for shares of Cardlytics in a research report issued to clients and investors on Monday, July 1st. William Blair analyst C. Shutler anticipates that the company will post earnings of ($0.28) per share for the quarter. William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Cardlytics’ Q3 2019 earnings at ($0.25) EPS, Q4 2019 earnings at ($0.09) EPS, FY2019 earnings at ($0.93) EPS, FY2020 earnings at ($0.27) EPS and FY2021 earnings at $0.53 EPS.
CDLX has been the topic of a number of other research reports. Zacks Investment Research raised shares of Cardlytics from a “sell” rating to a “hold” rating in a report on Monday, April 1st. SunTrust Banks reissued a “buy” rating and issued a $25.00 price target on shares of Cardlytics in a report on Wednesday, March 6th. KeyCorp raised their price target on shares of Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a report on Friday, May 10th. Finally, ValuEngine lowered shares of Cardlytics from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 23rd. Nine research analysts have rated the stock with a buy rating, The company presently has an average rating of “Buy” and a consensus target price of $22.71.
Shares of Cardlytics stock opened at $29.50 on Thursday. Cardlytics has a 12-month low of $9.80 and a 12-month high of $30.38. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.37 and a current ratio of 2.37. The stock has a fifty day moving average price of $23.85.
Cardlytics (NASDAQ:CDLX) last released its earnings results on Thursday, May 9th. The company reported ($0.30) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.61) by $0.31. Cardlytics had a negative net margin of 25.53% and a negative return on equity of 84.02%. The company had revenue of $35.99 million for the quarter, compared to analyst estimates of $36.11 million. During the same quarter last year, the firm earned ($0.35) EPS. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year.
In other Cardlytics news, Director Bryce Youngren sold 75,284 shares of the firm’s stock in a transaction on Thursday, June 6th. The shares were sold at an average price of $24.10, for a total value of $1,814,344.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Lynne Marie Laube sold 4,200 shares of the firm’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $30.00, for a total transaction of $126,000.00. The disclosure for this sale can be found here. In the last three months, insiders sold 296,984 shares of company stock worth $7,250,444. Insiders own 21.90% of the company’s stock.
A number of institutional investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its stake in shares of Cardlytics by 2.3% during the 1st quarter. SG Americas Securities LLC now owns 61,277 shares of the company’s stock valued at $1,014,000 after purchasing an additional 1,402 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Cardlytics by 0.4% during the 4th quarter. BlackRock Inc. now owns 422,718 shares of the company’s stock valued at $4,578,000 after purchasing an additional 1,610 shares in the last quarter. CIBC Private Wealth Group LLC boosted its stake in shares of Cardlytics by 6.7% during the 1st quarter. CIBC Private Wealth Group LLC now owns 37,745 shares of the company’s stock valued at $624,000 after purchasing an additional 2,375 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Cardlytics by 0.9% during the 4th quarter. Bank of America Corp DE now owns 270,025 shares of the company’s stock valued at $2,924,000 after purchasing an additional 2,471 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its stake in shares of Cardlytics by 80.0% during the 4th quarter. New York State Common Retirement Fund now owns 9,000 shares of the company’s stock valued at $97,000 after purchasing an additional 4,000 shares in the last quarter. 73.51% of the stock is currently owned by institutional investors and hedge funds.
About Cardlytics
Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company’s platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.